ALK and non-small cell lung carcinoma: Keynote 024 and Keynote 042 showed that compared with platinum-based chemotherapy, pembrolizumab monotherapy could significantly improve the OS of untreated advanced or metastatic NSCLC patients with PD-L1 positivity without EGFR or ALK alterations (23, 24, 27).